Immunocore Pipeline
Within oncology, we are designing ImmTAC® (Immune Mobilizing Monoclonal TCRs Against Cancer) molecules to treat patients with hematologic and solid tumours.
ImmTAC® molecules are engineered to activate a potent and T cell response to specifically kill target cancer cells.
The unique proposed mechanism of action provided by ImmTAC® molecules gives the potential to tackle diverse tumour types, including hematologic tumours and solid tumours, regardless of mutational burden or pre-existing immune infiltration.
We are investigating our ImmTAC® technology to target a diverse range of cancer indications.
CM-US--2400002
...
More Info Less Info